Generex Biotechnology Top-Line and Overall Valuation Bolstered By New Acquisitions and Puration Inc CBD Beverage Deal
November 30 2018 - 9:18AM
InvestorsHub NewsWire
Miramar, FL
-- November 30, 2018 -- InvestorsHub NewsWire -- Generex
Biotechnology Corp. (USOTC:
GNBT) today announced that Goldman Small Cap Research issued a
research update on the Company. The report reviews recently
announced acquisitions and a potentially lucrative agreement with
Puration, Inc. (USOTC:
PURA) To view the update report, along with disclosures and
disclaimers, visit http://www.GoldmanResearch.com.
Goldman
Small Cap Research Report
Highlights
In the
Opportunity Research update, analyst Rob Goldman discusses
Generex’s recent events and exciting upcoming opportunities that
lie ahead.
Goldman noted,
“Since our coverage initiation earlier this month, GNBT has
announced a series of deals that should serve as a precursor to
revenue and valuations gains in 2019. The Company continues to
execute on its strategy to become a nationwide, integrated,
end-to-end health care firm. GNBT has signed a LOI with 2 firms, in
which the Company will own 51%. Both deals should close this
quarter and a tender for the remaining 49% could occur next year.
These transactions will give GNBT exposure to the $23B wound care
market via a platform device that is cleared for 17 indications,
including diabetic ulcers, and the multi-billion-dollar ulcerative
colitis market via a pending 510(k) De Novo submission and trial.
Each of these categories represents favorable valuations, which
could be unlocked, beginning next year.”
“The Company’s
new CBD Product Agreement with Puration is game-changing. GNBT will
be introducing NuGenerex CBD HydroHealth High Alkaline Water to its
patient population and ever-growing pharmacy network. This
high value new offering will be infused with custom CBD extracts as
therapies for symptoms of specific health issues.
“
Goldman
concluded, “The aforementioned business development events projects
affirm our favorable outlook on these shares and we continue to
expect a higher overall valuation ahead for
GNBT.”
About
Goldman Small Cap Research: Founded in 2009 by former
Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman
Small Cap Research produces sponsored and non-sponsored small cap
and microcap stock research reports, articles, stock market blogs,
and popular investment newsletters.
Goldman Small
Cap Research is not in any way affiliated with Goldman Sachs &
Co.
This press
release contains excerpts of our most recently published
non-sponsored company research report on Generex Biotechnology
Corp. which carries a rating and a price target. The
information used and statements of fact made have been obtained
from sources considered reliable but we neither guarantee nor
represent the completeness or accuracy. Goldman Small Cap Research relied solely upon
information derived from Generex Biotechnology Corp. (“the
Company”) authorized press releases or legal disclosures made in
its filings with the U.S. Securities and Exchange Commission
http://www.sec.gov.
Separate from the factual content of our report about
the Company, we may from time to time include our own opinions
about the Company, its business, markets and opportunities. Any
opinions we may offer about the Company are solely our own, and are
made in reliance upon our rights under the First Amendment to the
U.S. Constitution, and are provided solely for the general
opinionated discussion of our readers. Our opinions should not be
considered to be complete, precise, accurate, or current investment
advice. Statements herein may contain forward-looking statements
and are subject to significant risks and uncertainties affecting
results.
A Goldman Small
Cap Research report, update, newsletter, article, trading alert,
corporate profile, or press release is not intended as an offering,
recommendation, or a solicitation of an offer to buy or sell the
securities mentioned or discussed is to
be used for informational purposes only. Please read
all associated full disclosures, disclaimers, and analyst
background on our website before investing. Neither Goldman Small
Cap Research nor its parent is a registered investment adviser or
broker-dealer with FINRA or any other regulatory agency. To
download this research report or any of our research, view our
disclosures and disclaimers, or for more information, visit
www.goldmanresearch.com. Goldman Small Cap
Research was not compensated for the production or distribution of
this update or press release by any company mentioned in this
update or press release. On a year-to-date basis, Goldman Small Cap
Research was compensated $5500 by Puration, Inc. the Company for
research and distribution services.
About
Generex Biotechnology Corp. (OTC
- GNRX) Generex Biotechnology Corp. is a strategic,
diversified healthcare holdings company with offerings in a variety
of services, diagnostics, medical devices, and pharmaceutical
development. The Company’s direct-to-patient services support its
strategy of all-inclusive access to doctors, diagnostics,
therapeutics, and additional health-related services to greatly
improve the patient experience in receiving care. Generex’s
management services remove administrative burdens in multiple
provider settings, including private practice and hospital,
allowing doctors to devote more time to patient care. The Company
also is engaged in clinical advancement of its wholly owned
therapeutic products with a focus in immunotherapeutics and its
proprietary buccal administration of insulin.
Puration, Inc.
is a leading Texas-based, CBD-infused beverage
provider.
For more
information, please visit: www.Generex.com
Goldman Small
Cap Research
Rob Goldman,
Analyst
410-609-7100
rob@goldmanresearch.com
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024